skip to content
Overdose : how excessive government regulation stifles pharmaceutical innovation Preview this item
ClosePreview this item
Checking...

Overdose : how excessive government regulation stifles pharmaceutical innovation

Author: Richard Allen Epstein; Yale University. Institute for Policy Innovation.
Publisher: New Haven : Yale University Press, ©2006.
Edition/Format:   Book : EnglishView all editions and formats
Database:WorldCat
Summary:
This book is the first to offer a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. Richard A. Epstein looks closely at the regulatory framework that surrounds all aspects of making pharmaceutical products today, and he assesses which current legal and regulatory practices make sense and which have gone  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Additional Physical Format: Online version:
Epstein, Richard Allen, 1943-
Overdose.
New Haven : Yale University Press, c2006
(OCoLC)654630536
Material Type: Internet resource
Document Type: Book, Internet Resource
All Authors / Contributors: Richard Allen Epstein; Yale University. Institute for Policy Innovation.
ISBN: 0300116640 9780300116649
OCLC Number: 64688339
Notes: "An Institute for Policy Innovation Book."
Description: xi, 283 p. ; 25 cm.
Contents: Rising expectations--
and diminishing returns --
Property generally : externalities, coordination, and the public domain --
Intellectual property: the public domain and private rights --
Taming conflict of interests --
Federally sponsored research under Bayh-Dole --
The anticommons --
The single monopoly : current patent limitations --
Rate regulation : an unneeded swamp --
Patent purchases: a second swamp --
Socialization of R & D : the final swamp --
The steady expansion of FDA power --
FDA versus the individual : upstream or downstream decision making --
Drug withdrawal : too much, too soon --
Getting the drugs to market --
Deceptive marketing --
Tort preliminaries --
Product liability for prescription drugs : manufacturing and design cases --
The main event : misrepresentation, overpromotion, and duty to warn --
Conclusion : socialized medicines.
Responsibility: Richard A. Epstein.
More information:

Abstract:

Offers a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. This book looks at the  Read more...

Reviews

Editorial reviews

Publisher Synopsis

In recent years, the pharmaceutical industry has come under often one-sided criticism from observers such as Marcia Angell. This book, while sure to be controversial, is in large part a healthy Read more...

 
User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


<http://www.worldcat.org/oclc/64688339>
library:oclcnum"64688339"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/64688339>
rdf:typeschema:Book
schema:about
<http://id.worldcat.org/fast/1060149>
rdf:typeschema:Intangible
schema:name"Pharmaceutical industry--Government policy."@en
schema:name"Pharmaceutical industry--Government policy"@en
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
<http://viaf.org/viaf/125184247>
rdf:typeschema:Organization
schema:name"États-Unis. Food and Drug Administration."
schema:about
schema:about
schema:about
<http://viaf.org/viaf/151271988>
rdf:typeschema:Organization
schema:name"United States. Food and Drug Administration."
schema:about
schema:about
schema:about
schema:contributor
<http://viaf.org/viaf/136259678>
rdf:typeschema:Organization
schema:name"Yale University. Institute for Policy Innovation."
schema:copyrightYear"2006"
schema:creator
schema:datePublished"2006"
schema:description"Rising expectations-- and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R & D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawal : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines."@en
schema:description"This book is the first to offer a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. Richard A. Epstein looks closely at the regulatory framework that surrounds all aspects of making pharmaceutical products today, and he assesses which current legal and regulatory practices make sense and which have gone awry. While critics of pharmaceutical companies call for ever more stringent controls on virtually every aspect of drug development and approval, Epstein cautions that the effect of such an approach will be to stifle pharmaceutical innovation and slow the delivery of beneficial treatments to the patients who need them. The author considers an array of challenges that confront the industry--conflicts of interest among government, academe, and the drug companies; intellectual property rights that govern patents; FDA regulation; pricing disputes; marketing practices; and liability issues, including those brought to light in the recent VIOXX case. Epstein argues that to ensure the continuing creativity, efficiency, and success of the pharmaceutical industry, the best system will feature strong property rights and clearly enforceable contracts, with minimal regulatory and judicial interference."@en
schema:exampleOfWork<http://worldcat.org/entity/work/id/197835569>
schema:inLanguage"en"
schema:name"Overdose : how excessive government regulation stifles pharmaceutical innovation"@en
schema:numberOfPages"283"
schema:publisher
schema:url
schema:workExample
umbel:isLike<http://bnb.data.bl.uk/id/resource/GBA667981>

Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.